All About Multiple Sclerosis

More MS news articles for April 2003

Long-Term Study of Interferon System State in Patients with Multiple Sclerosis Received the Individual Immune Therapy with Human Recombinant IFN-alpha

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12687205&dopt=Abstract

Russ J Immunol 2001 Apr;6(1):39-46
Cheknev SB, Kobyakina NA, Mezentseva MV, Skvortsova VI.
N.F. Gamaleya Epidemiology and Microbiology Institute, Russian Academy of Medical Science, Moscow, Russia.

Three patients with an evident multiple sclerosis (MS) were observed in a dynamics of long-term immune therapy based on administration of rIFN-alpha preparation.

Production of IFN-alpha and IFN-gamma by induced peripheral blood leukocytes (PBL) of the patients was tested simultaneously with detection of a response of PBL to in vitro IFN-alpha and IFN-beta priming action every 10th day of observation.

It has been shown that positive clinical effect of rIFN-alpha therapy was associated with a partial restoration of initially decreased IFN-alpha and IFN-gamma production by PBL, and paralleled by increasing the cell IFN-alpha sensitivity.

On the other hand, decrease of PBL response to in vitro IFN-beta action was related to augmentation of IFN-alpha and IFN-gamma production in the secondary progressive MS.

The effect of rIFN-alpha administration on blood cell sensitivity to in vitro IFN-beta treatment was manifested by augmentation of PBL response in patient with the remitting MS.

The data obtained allowed to suggest a possibility to combine a usage of rIFN-beta and rIFN-alpha in pathogenetical therapy of the remitting MS.